A dual-antigen mRNA-lipid polyplex vaccine elicits durable multistage immunity and sterile protection against malaria in mice - PubMed
3 hours ago
- #malaria vaccine
- #mRNA-LPP platform
- #dual-antigen immunity
- The study develops a dual-antigen mRNA-lipid polyplex (LPP) vaccine called Mal05, targeting both pre-erythrocytic and blood stages of malaria by encoding PfCSP and PfRH5 antigens.
- Mal05 demonstrated efficient antigen expression, induced durable high-titer antibodies, and inhibited sporozoite invasion and erythrocytic growth in vitro in mouse models.
- The vaccine elicited robust Th1-biased CD4+ and CD8+ T-cell responses and provided 100% sterile protection in mice challenged with transgenic Plasmodium berghei expressing PfCSP.
- This approach combines neutralizing antibodies with strong cellular immunity, offering a potential next-generation multistage vaccine strategy for complex pathogens like malaria.